TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12399201
Drug: 10 micro
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Study: 12399201
Drug: 20 micro
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Study: 7746026
Drug: Eferox 100
Normalized name: Aloe ferox leaf
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eferox 100 tablets (100 micrograms levothyroxine‐Na)
Study: 7746026
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (100 micrograms levothyroxine‐Na)
Study: 2646206
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg twice a day
Study: 1215859
Drug: tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tetracycline HCl 1 g
Study: 1215859
Drug: tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tetracycline HCl + terpenes 100 mg
Study: 1215859
Drug: minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: minocycline 200 mg
Study: 1215859
Drug: cotrimoxazole (sulfamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: cotrimoxazole (sulfamethoxazole 1.6 g + trimethoprim 320 mg)
Study: 31763286
Drug: Oral Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Ivermectin (6 mg each, two doses 24 hours apart)
Study: 29333775
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 μg·kg⁻¹ bolus, saline diluted to 10 mL, followed by maintenance dose of 0.1-0.4 mL·(kg·h)⁻¹ until 45 min before the end of operation)
Study: 29333775
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (10 mL bolus, followed by maintenance dose of 0.1-0.4 mL·(kg·h)⁻¹ until 45 min before the end of operation)
Study: 15498605
Drug: MSL-109 15
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSL-109 15 mg
Study: 15498605
Drug: MSL-109 60
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSL-109 60 mg
Study: 11430552
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) 0.25 mg/kg body weight (ICG1)
Study: 11430552
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) 0.25 mg/kg body weight (ICG2)
Study: 11430552
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin 20% 1.75 ml/kg body weight (Group ALB)
Study: 11430552
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 6% 5.25 ml/kg body weight (Group HAES)
Study: 11430552
Drug: Polygelatine 3.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polygelatine 3.5% 7.0 ml/kg body weight (Group HAEM)
Study: 7818586
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice a day for 4 weeks
Study: 3337412
Drug: One-dose activated
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose activated charcoal (50 g)
Study: 3337412
Drug: Two-dose activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose activated charcoal (50 g)
Study: 3337412
Drug: Three-dose activated
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose activated charcoal (50 g)
Study: 21173495
Drug: Waon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waon therapy (daily for 4 weeks)
Study: 21173495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard optimal medications for CHF)
Study: 15070944
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss with PEG-OB treatment
Study: 15070944
Drug: PEG-OB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-OB treatment
Study: 9492731
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg intravenous infusion before operation and again 8 hours later)
Study: 3128132
Drug: Nitroglycerin infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion, 1 to 2 micrograms.kg‐1.min‐1
Study: 3128132
Drug: No nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nitroglycerin infusion
Study: 22488751
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment with rectal balloon training and pelvic floor muscle training
Study: 22488751
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of constipating medication
Study: 18633251
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6.0 day 1 and paclitaxel 70 mg/m2 day 1, 8, 15 every 4 weeks followed by gemcitabine 1.0 g/m2 day 1, 8, 15 every 4 weeks (Group CP)
Study: 18633251
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 2.0 and gemcitabine 0.8 g/m2 day 1, 8 every 3 weeks followed by docetaxel 60 mg/m2 day 1, 8 every 3 weeks (Group CG)
Study: 10224335
Drug: Rifametane (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifametane (300 mg single oral dose)
Study: 10224335
Drug: Rifampicin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (300 mg single oral dose)
Study: 12202968
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg/day)
Study: 6742536
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg for <65 years; 0.085 mg/kg for ≥65 years)
Study: 6742536
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg/kg for <65 years; 0.15 mg/kg for ≥65 years)
Study: 26083427
Drug: Lidocaine (2%)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (2%) via intravenous bolus (1.5 mg/kg) followed by infusion at 2 mg/kg/h until the end of surgery
Study: 24291444
Drug: Active music
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active music therapy control
Study: 17666280
Drug: Alternative non-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative non-heparin anticoagulants (danaparoid, lepirudin, argatroban)
Study: 16135578
Drug: Drospirenone 3
Normalized name: drospirenone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 3 mg and Ethinyl Estradiol 20 microg (24/4 regimen)
Study: 11906496
Drug: Clinafloxacin monotherapy
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinafloxacin monotherapy (200 mg every 12 h)
Study: 11906496
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g every 8 h) plus Amikacin (15 mg/kg per day)
Study: 2405347
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro antibody production of HIV‐specific IgG
Study: 25872505
Drug: Online self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-help program (deprexis®) with 12 weekly tasks during inpatient treatment
Study: 25872505
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to an online platform with weekly updated information on depression
Study: 19728564
Drug: Compounds 1-7
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compounds 1-7
Study: 19728564
Drug: Compounds 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounds 1, 3, 4, 5, 6, and 7
Study: 19728564
Drug: Compound 5
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound 5
Study: 9032106
Drug: Nisoldipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (20-40 mg once daily)
Study: 21780182
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (0.8 mg folic acid, 0.5 mg vitamin B12, 20 mg vitamin B6)
Study: 12358304
Drug: Topical instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical instillation of non-selective beta-adrenoceptor antagonist (timolol)
Study: 12358304
Drug: Topical instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical instillation of selective beta-adrenoceptor antagonist (betaxolol)
Study: 9103279
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of salicylates
Study: 15926987
Drug: Heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuit
Study: 10148570
Drug: Non heparin-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non heparin-coated circuit with systemic heparin
Study: 29124826
Drug: Sequential delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential delivery of HE intervention
Study: 29124826
Drug: Sequential nudge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential nudge intervention delivery
Study: 20456841
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (Group A)
Study: 16100296
Drug: Crushed tablets
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablets mixed in 240 mL nutritional supplement drink followed by 120 mL water
Study: 16100296
Drug: Whole tablets
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tablets swallowed with 240 mL water
Study: 26811090
Drug: Saffron (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (300 mg/day for 10 days)
Study: 24535415
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) at dosages of 1.2, 2.4, and 4.8 g/day for 6 weeks
Study: 24535415
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) at high dosage (4.8 g/day)
Study: 9495423
Drug: Dextromethorphan 45
Normalized name: BUPROPION 105MG/DEXTROMETHORPHAN 45MG TAB,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 45 mg
Study: 17110451
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K supplementation (150 mug daily for 6 months)
Study: 12468788
Drug: Gait trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gait trainer therapy (2 weeks)
Study: 12468788
Drug: Treadmill therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treadmill therapy (2 weeks)
Study: 8605522
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine (rBS/WC)
Study: 2686256
Drug: Aspirin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (500 mg/day) added to nitrates, beta-blockers, and calcium entry blockers
Study: 2686256
Drug: Nitrates, beta-blockers,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates, beta-blockers, and calcium entry blockers (without aspirin)
Study: 4610853
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment within the first 24 hours of thermal injuries
Study: 25773378
Drug: Alirocumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (150 mg)
Study: 20370312
Drug: BIT (Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIT (Behavioral Internet Treatment)
Study: 15999906
Drug: Psychotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drugs (sedative and non-sedative neuroleptics, antidepressants, tranquilizers, hypnotics, psychostimulants, cognition-enhancing drugs)
Study: 12113585
Drug: PSAV cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSAV cutoff of 0.75 ng/mL/year
Study: 12113585
Drug: PSAV cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSAV cutoff of 0.10 ng/mL/year
Study: 2188479
Drug: mianserin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (up to 90 mg per day)
Study: 2188479
Drug: maprotiline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: maprotiline (up to 150 mg per day)
Study: 6117728
Drug: Drugs to
Normalized name: soap/herbal drugs TOPICAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs to induce initial remission
Study: 24817242
Drug: Rhinotopic protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinotopic protocol consisting of twice-daily saline rinses, nebulized corticosteroid, and nebulized antibiotic for 6 weeks, followed by once-weekly endoscopic sinus debridement and topical intrasinus installation of corticosteroid and antibiotic.
Study: 22284902
Drug: HM30181 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 180 mg single-dose
Study: 22284902
Drug: HM30181 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 360 mg single-dose
Study: 22284902
Drug: HM30181 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 600 mg single-dose
Study: 22284902
Drug: HM30181 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 900 mg single-dose
Study: 22284902
Drug: HM30181 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 60 mg multiple-dose
Study: 22284902
Drug: HM30181 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 180 mg multiple-dose
Study: 22284902
Drug: HM30181 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 360 mg multiple-dose
Study: 22284902
Drug: HM30181 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 (all doses)
Study: 22284902
Drug: HM30181 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 (multiple doses)
Study: 22284902
Drug: HM30181 (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 (360 mg repeated administration)
Study: 15920044
Drug: C therapy
Normalized name: CARDIAC THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: C therapy (combination therapy weight loss program for 2 years)
Study: 15920044
Drug: S/C therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/C therapy (standard therapy weight loss program for 1 year followed by combination therapy in the 2nd year)
Study: 13679972
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with biologically standardized mushroom extract at a maintenance dosage of 0.1 mg/ml of Alt a I
Study: 13679972
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with biologically standardized mushroom extract
Study: 10479145
Drug: Nonavalent pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonavalent pneumococcal conjugate vaccine
Study: 29074892
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication for 14 days (Control)
Study: 23949016
Drug: G-Bond (HEMA-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond (HEMA-free one-step adhesive)
Study: 17662129
Drug: Pimecrolimus (Elidel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus (Elidel cream 1%)
Study: 16098458
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of imatinib daily
Study: 16098458
Drug: Cross-over to
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over to high-dose imatinib after progression on 400 mg
Study: 16098458
Drug: Cross-over to
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over to high-dose imatinib
Study: 8583020
Drug: Modified Widman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Widman flap surgery and scaling and root planning with ibuprofen
Study: 2407812
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy (tamoxifen 20 mg/d and low-dose prednisone 7.5 mg/d for one year)
Study: 2407812
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no adjuvant therapy)
Study: 7355185
Drug: 10 compound
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 compound CS‐US trials
Study: 7355185
Drug: 30 compound
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 compound CS‐US trials
Study: 7355185
Drug: 30 compound
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 compound CS presentations and 30 shock stimuli (Control group)
Study: 28982775
Drug: Virtual asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Virtual asthma clinic (VAC) with 8-monthly outpatient visits and monthly web-based monitoring
Study: 28982775
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with 4-monthly outpatient visits
Study: 19556410
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine digluconate oral care
Study: 19556410
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care without antiseptic
Study: 15081447
Drug: Caffeine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of brewed coffee)
Study: 8288717
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg E3 suppository
Study: 15840256
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg once daily for 1 week
Study: 15840256
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg once daily for 1 week
Study: 31894102
Drug: Deworming (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deworming (1 year after treatment)
Study: 10924732
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (1 g/day)
Study: 9311486
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg.kg-1 in 250 mL of saline
Study: 3724308
Drug: Flunitrazepam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1.0 mg
Study: 24007748
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg/day on days 1-21) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22)
Study: 24007748
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (40 mg/day on days 1-4, 9-12, and 17-20)
Study: 27096106
Drug: Pomalidomide plus
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide plus low-dose dexamethasone
Study: 20215781
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (Vi-E) treatment on the blood-side layer of a synthetic polysulfone dialyzer
Study: 20215781
Drug: Polysulfone (PS)
Normalized name: solasulfone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysulfone (PS) dialyzer without Vi-E treatment
Study: 16609356
Drug: [99mTc]pertechnetate salivary
Approvals — FDA: no, EMA: no, PMDA: no
Description: [99mTc]pertechnetate salivary gland scintigraphy (SGS) after intravenous injection of 370 MBq
Study: 10720082
Drug: Ro 45-2081
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 45-2081 (50 mg, single intravenous injection)
Study: 8874590
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin (20 micrograms)
Study: 24448692
Drug: Topiroxostat 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 160 mg/day
Study: 15821394
Drug: Atazanavir/ritonavir (ATV/RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATV/RTV) (300/100 mg) once daily
Study: 15821394
Drug: Lopinavir/ritonavir (LPV/RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/RTV) (400/100 mg) twice daily
Study: 15821394
Drug: Atazanavir/saquinavir (ATV/SQV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/saquinavir (ATV/SQV) (400/1200 mg) once daily
Study: 10224988
Drug: Education through
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education through monthly newsletters
Study: 2069516
Drug: Surfactant inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant inhalation (1 ml; 10 mg per milliliter)
Study: 29579846
Drug: HTK +
Normalized name: Histidine-Tryptophan-Ketoglutarate Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTK + UW solution
Study: 26728882
Drug: Combination HIV-prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HIV-prevention intervention
Study: 18173139
Drug: Erzhi Tiangui
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erzhi Tiangui Granule (ETG) combined with Western medicine
Study: 15309433
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil (EVOO) 40 mL/day
Study: 15309433
Drug: Refined olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined olive oil (ROO) 40 mL/day
Study: 12126548
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH), 4.5 U Bid for 5‐7 days
Study: 7586252
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 15 g infused over 24 hours